Denosumab治疗骨转移效果好吗？

Malignant tumors most prone to bone metastasis include breast cancer, lung cancer, kidney cancer, rectal cancer, pancreatic cancer, gastric cancer, colon cancer, ovarian cancer, prostate cancer, etc. On May 28, 2010, the European Commission approved the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients for whom other current treatments are ineffective or intolerable to reduce the risk of fractures. Is Denosumab effective in treating bone metastasis?

For solid tumor bone metastasis, the safety and efficacy data of Denosumab come from three global randomized, double-blind controlled trials, namely Study 20050136, Study 20050244 and Study 20050103.

In the three trials, patients were randomly assigned to receive either denosumab (120 mg every four weeks) or zoledronate (4 mg every four weeks). Patients with creatinine clearance less than 30 mL/min were excluded. The primary endpoint of the trial was time to first bone-related events (SREs) that was non-inferior to zoledronic acid.

The above three test results show that compared with zoledronic acid, it effectively delays the occurrence of the first bone-related event. Lung cancer and other solid tumors (including multiple myeloma): Denosumab: 20.5 months vs. zoledronic acid: 16.3 months. Lung cancer and other solid tumors (excluding multiple myeloma): Denosumab: 21.4 months vs. zoledronic acid: 15.4 months. Prostate cancer bone metastases: Denosumab: 20.7 months vs. zoledronic acid: 17.1 months. Breast cancer bone metastases: 60% of patients in the Denosumab group had no serious bone-related events at 27 months vs. more than 50% of patients in the zoledronic acid group who had a serious bone-related event before the end of the trial.